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During embryogenesis, bone morphogenetic protein
(BMP) signaling needs to be finely tuned in a locally
restricted manner. Here, we report a cell-intrinsic
mode of BMP response control executed by the
membrane protein Jiraiya. In the Xenopus embryo,
zygotic Jiraiya, expressed exclusively in the neuro-
ectoderm, is essential and sufficient for limiting
dorsal neural development, which is dependent on
BMP signals. In animal cap assays, Jiraiya selectively
and cell-autonomously inhibits BMP signaling, while
Jiraiya’s knockdown enhances the signaling. In the
cell, Jiraiya selectively forms a complex with type II
BMP receptor (BMPRII) and downregulates the cell
surface localization of functional BMPRII. This
functional interaction with Jiraiya depends on the
unique tail domain of BMPRII, and, in particular, the
conserved EVNNNG motif, the function of which
has been unknown. Thus, Jiraiya represents a cell-
intrinsic cutoff mechanism for dynamic responsive-
ness to BMP signals via subtype-selective receptor
control.
INTRODUCTION
One intriguing concept drawn from previous studies is that
bone morphogenetic protein (BMP) signal inhibition plays active
roles in various aspects of embryogenesis (reviewed in De
Robertis and Kuroda, 2004). A typical example is the Spemann’s
organizer-derived neural inducers (e.g., Chordin and Noggin),
which act by binding and antagonizing BMP signals in the extra-
cellular space (Lamb et al., 1993; Sasai et al., 1994; Piccolo et al.,
1996; Zimmerman et al., 1996). Animal cap explant studies have
shown that this inhibition of BMP signals is essential and suffi-
cient for neural induction in the Xenopus ectoderm (Sasai
et al., 1995).
In addition, the antagonistic activity of the Spemann organizer
factor Chordin is finely regulated by a number of extracellular
cofactors and proteases, such as Twisted gastrulation (Oel-
geschla¨ger et al., 2000), BMP1/Xolloid-class proteases (PiccoloDevelopmet al., 1997; Lee et al., 2006), and the scaffold protein ONT1
(Inomata et al., 2008). BMP signaling is also modulated at the
intracellular mediator level. Inside cells, Smad1, a regulatory
Smad for BMP, is negatively controlled by MAPK-dependent
phosphorylation at its hinge region (Pera et al., 2003). Ectoder-
min, a maternal E3 uniquitin ligase, targets and promotes the
inactivation of Smad4 (co-Smad), while the HECT-domain ubiq-
uitin ligase Smurf1 plays a role in Smad1 degradation (Dupont
et al., 2005; Zhu et al., 1999).
Once the neuroectoderm (or presumptive neural plate) is
determined in the early gastrula ectoderm, further regional
patterning along the dorsoventral (DV) and anterior-posterior
axes then takes place within this tissue. In this process, BMP
signals are involved in the specification of presumptive dorsal
neural tissues (which correspond to the lateral neuroectoderm
before neural tube closure [Liu and Niswander, 2005]), whereas
Shh plays a major role in the ventral specification, including floor
plate andmotoneuron differentiation (reviewed in Briscoe, 2009).
Multiple BMP ligands (e.g., BMP4 and Gdf7; Liem et al., 1995;
Lee et al., 1998) are expressed in the nonneural ectoderm and
at the neural/nonneural boundary (neural fold and roof plate).
BMP signals produced there play an instructive role in the devel-
opment of the presumptive dorsal neural tissues and the neural
fold-derived neural crest (Liem et al., 1995, 1997; Furuta et al.,
1997). BMP signals induce the expression of dorsal neural-
specific transcription factors, such as Pax3 and Msx1 (Liem
et al., 1995; Furuta et al., 1997), whereas Shh signals suppresses
their expression (Liem et al., 1995).
The core BMP receptors (BMPRs) consist of a heterotetramer
of type I and type II BMPR subunits (BMPRI and BMPRII, respec-
tively). BMPRII is a transmembrane protein with a constitutively
active kinase domain, and it phosphorylates BMPRI upon
binding to BMP ligands. BMPRI then activates the Smad
pathway by phosphorylating Smad1/5/8 (Wu and Hill, 2009;
Moustakas and Heldin, 2009; Miyazono et al., 2010). In addition,
previous studies have revealed diverse non-Smad pathways
and their roles in BMPR signaling (Shibuya et al., 1998; Foletta
et al., 2003). In general, compared with the molecular controls
of the intracellular mediators of BMP signaling, the under-
standing of dynamic regulation at the BMPR level is still limited
in vertebrate embryogenesis. Bambi, a BMP pseudoreceptor,
has been isolated as an intriguing BMP-synexpression factor
(Onichtchouk et al., 1999). The GPI-anchored membrane
protein, DRAGON, is likely to facilitate the ligand-receptorental Cell 19, 547–561, October 19, 2010 ª2010 Elsevier Inc. 547
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mostly remain elusive.
In this report, we introduce a transmembrane protein, Jiraiya,
which is indispensable for the proper control of BMP signaling
during early Xenopus embryogenesis. Zygotic Jiraiya is
expressed in the neuroectoderm and required for proper DV
patterning of the neural tissues. Jiraiya, the cytoplamic localiza-
tion of which is enriched in the ER system, forms a complex with
BMPRII protein and reduces the level of functional BMPRII on the
cell surface, thereby attenuating the cellular responsiveness to
BMP signals in a region-specific manner. Thus, Jiraiya is an
essential anti-BMP factor acting at the receptor level during early
neuroectodermal patterning.
RESULTS
Isolation of Jiraiya and Its Expression
in the Neuroectoderm
Jiraiya was isolated in our previous differential screen for down-
stream genes of Chordin in the animal cap assay (clone #308;
AB075972; Sasai et al., 2001). The gene was named according
to its expression on the dorsal side of the frog (Jiraiya is a samurai
hero in Japanese Kabuki drama, who fights his enemies while
riding on the back of a giant magic frog [http://www.cdb.riken.
jp/sasai/jiraiya.html]). Jiraiya encodes a transmembrane protein
that shows no significant homology with any other proteins in
the database. The Jiraiya protein consists of a short extracellular
domain without an N-glycosylation site, three transmembrane
domains, and a relatively long intracellular domain in the
carboxyl (C)-terminal region (Figure 1A). A Jiraiya homolog is
found in the mouse and human genomes (NT_039462.7 and
NT_011295.11). Consistent with the screening strategy, Jiraiya
expression was induced by Chordin in the animal cap
(Figure 1B, lane 2).
Whole-mount in situ hybridization analysis showed the
diffuse expression of maternal Jiraiya on the animal side (see
Figure S1A available online) that largely disappeared by the
late blastula stage. Zygotic Jiraiya expression started in the
dorsal ectoderm (neuroectoderm) between the early and mid-
gastrula stages (Figures 1C; arrowhead, the dorsal lip). At the
neurula stage, Jiraiya expression was limited to the neural plate
(Figure 1D; Figure S1B). After the closure of the neural tube,
strong Jiraiya expression was observed in the dorsal neural
tube (Figures 1E and 1F) (except in the dorsal-most part
including the roof plate) and also later in the developing retina
(not shown).
Jiraiya expression was devoid of themidline (floor plate) region
of the neural plate (Figure 1D). In accordance with this pattern,
Shh, which promotes the differentiation of the floor plate tissue,
suppressed Jiraiya expression in Chordin-injected neuralized
animal caps (Figure 1B, lane 3).
Jiraiya Is Required for the Formation of Dorsal Neural
Tissues in the Xenopus Embryo
We next performed zygotic Jiraiya-specific knockdown with
splice-interfering Jiraiya morpholinos (Jiraiya-MO) (Figures S1C
and S1D for control). The injection of Jiraiya-MO into the four-
cell stage embryo did not substantially affect the expression of
Sox2 or Chordin (Figures S1E–S1H). In contrast, the unilateral548 Developmental Cell 19, 547–561, October 19, 2010 ª2010 ElsevJiraiya-MO injection expanded the expression of the dorsal
neural tube markers Pax3 and Msx1 (80% [n = 10] and 80%
[n = 10], respectively) (Figures 1G and 1I). The control MO (five
base mismatched [5mis-MO]) did not induce the expansion of
these dorsal markers (n = 13) (Figures S1I–S1L, shown by bilat-
eral injection). In addition, the expansion of the dorsal markers
was reversed by coinjecting Jiraiya mRNA (no strong expansion
in 78% [n = 14] and 84% [n = 13], respectively) (Figures 1H and
1J). Conversely, the ventral neural markersNkx2.2 andHB9were
suppressed by Jiraiya-MO (100% [n = 10] and 100% [n = 11],
respectively) (Figures S1M–S1P). Jiraiya-MO also induced
Pax3 andMsx1 in the animal cap neuralized by Chordin (Figures
1K and 1L), but not Sox2 (Figure 1M). Conversely, the injection
of Jiraiya inhibited the expression of Pax3 and Msx1 (both 91%
[n = 12]) (Figures 1N and 1O), but not Sox2 (Figure 1P) orChordin
(Figure 1Q).
These findings show that Jiraiya play an indispensable role in
limiting the extent of dorsal neural development to the proper
level.
Jiraiya Interferes with BMP Signaling
at the Receptor Level
A number of previous studies have shown that BMP signaling
plays a key role in dorsal neural development (reviewed in Liu
and Niswander, 2005). Immunostaining analysis showed that
Jiraiya-MO injection markedly increased the level of phosphor-
ylated Smad1/5/8 (pSmad1, hereafter) in the dorsal neural tube
as compared with that in the control embryo and expanded
its positive area on the injected side (Figures 2A and 2B, arrow-
heads). We next tested the effect of Jiraiya-MO on pSmad1
level in the animal cap neuralized by a moderate dose of
Chordin (50 pg/cell) (Figure 2C) (this Chordin mRNA injection
only transiently increases Chordin protein during neural
induction at the early gastrula stages, but not substantially at
later stages), and observed that Jiraiya-MO caused a clear
accumulation of pSmad1 (Figure 2D). These loss-of-function
data suggest that Jiraiya plays an essential role in the sup-
pression of BMP signaling in the embryonic neuroectodermal
tissue.
We next examined the effect of Jiraiya on the expression of
Msx1, a gene directly downstream of BMP signaling (Suzuki
et al., 1997; Ramos and Robert, 2005), in the neuralized animal
cap assay. The induction of Msx1 expression by Jiraiya-MO
(Figure 2E, lane 2) was inhibited by the coinjection of BMP4-
MO (lane 4). Conversely, the Msx1 expression induced by
BMP4 protein treatment in the animal cap cells was further
augmented by Jiraiya-MO (Figure 2F, lanes 3 and 4). Taken
together, these findings suggest that Jiraiya works in the anti-
BMP direction in vivo and in vitro.
In western blot analysis (Figures 3A and 3B), the undissoci-
ated animal cap tissue showed a substantial level of pSmad1
(Figure 3B, lane 1). This endogenous level of pSmad1 was
clearly suppressed by Jiraiya (lanes 2 and 3). Consistent with
this, a luciferase reporter assay for BMP signaling (BRE-luc)
revealed that Jiraiya strongly reduced the luciferase activity
in both the BMP4 (RNA)-uninjected and -injected animal
caps (Figure 3C, lanes 2 and 5, compare with lanes 1 and 4).
Conversely, the knockdown of Jiraiya enhanced the BRE-
reporter activity (Figure 3D, lanes 1 and 2) (in this early-stageier Inc.
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Figure 1. The Transmembrane Protein Jiraiya is Expressed in the Neuroectoderm and Required for Proper Dorsal Neural Development
(A) Deduced protein structure of Jiraiya. The gray box shows signal peptide (SP); the black box shows transmembrane domain (TM).
(B) Quantitative PCR analysis showing the expression of Jiraiya in uninjected control animal caps (AC) and neuralized animal caps byChordin (Chd) with or without
Sonic hedgehog (Shh). Chordin (12.5 pg/cell) and Shh mRNA (100 pg/cell) were injected into four cell embryos. Animal caps were dissected at stage 9 and
cultured until stage 15.
(C–F) Whole-mount in situ hybridization analysis of Jiraiya expression. (C) Early gastrula stage, sagittal section. Arrowhead, dorsal lip. (D) Early neurula stage,
dorsal view. (E and F) Tailbud embryo, dorsal view and neural tube cross-section. nc, notochord; nt, neural tube; so, somite.
(G–J) The expression of dorsal neural markers at the neurula stage. Jiraiya-MO (6 ng/cell) and VenusmRNA (200 pg/cell) were unilaterally injected into two animal
blastomeres of eight-cell stage embryos with (H and J) or without (G and I) Jiraiya mRNA (200 pg/cell).
(K–M) Quantitative PCR analysis of Pax3 (K),Msx1 (L), and Sox2 (M) expression in neuralized animal caps. Jiraiya-MO (25 ng/cell) or a control MO (25 ng/cell; five
base mismatched) was injected into all the blastomeres of four-cell embryos with Chordin mRNA (50 pg/cell). Animal caps were cultured until stage 22.
(N–Q) JiraiyamRNA (400 pg/cell) and VenusmRNA (200 pg/cell) were unilaterally injected into two animal blastomeres of eight-cell stage embryos. Embryos were
fixed at stage 14 and whole-mount in situ hybridization was performed with the Pax3 (N), Msx1 (O), Sox2 (P), and Chordin (Q) probes.
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Figure 2. Depletion of Jiraiya Enhances the BMP Signaling in Neural
Tissues
(A and B) Immunostaining for phosphorylated Smad1/5/8 (pSmad1) in cryo-
sections of the dorsal neural tube of tailbud embryos. Jiraiya-MO (12 ng/cell)
or control MO (12 ng/cell) was injected into two animal blastomeres of eight-
cell embryos with a cell-lineage tracer (Lyn-Venus mRNA; 5 pg/cell).
(C) Schematic of the experiment of neuralized animal cap assay. Chordin
mRNA (50 pg/cell), Lyn-Venus mRNA (5 pg/cell), and MOs (12 ng/cell) were
injected in the indicated fashion.
(D) Cryosections of neuralized animal caps (stage 22 equivalent) were immu-
nostained for pSmad1 and Lyn-Venus.
(E and F) Quantitative PCR analysis of the expression of Msx1 in animal cap
cells neuralized by Chordin protein treatment. (E) Jiraiya-MO (25 ng/cell),
control MO (25 ng/cell), and BMP4-MO (6 ng/cell) were injected into all
blastomeres of four-cell embryos. Animal caps were dissected at stage 9,
then the protein-impermeable outer layer was removed by transient dissocia-
tion in CMFM, and the inner layer cells were then reaggregated in LCMR con-
taining 1 mg /ml Chordin protein and cultured until stage 15. (F) Inner-layer cell
aggregates were treated with Chordin protein as in (E), and cultured until stage
13. Then, for uniform BMP protein treatment, the aggregates were rinsed,
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550 Developmental Cell 19, 547–561, October 19, 2010 ª2010 Elsevanalysis, a Jiraiya MO against the 50UTR was used) (Figures
S2A–S2C), and this enhanced reporter activity was reversed
by the coinjection of Jiraiya RNA (coding sequence only)
(Figure 3D, lane 4).
In dissociated animal cap cells, pSmad1 was detected only at
a low level (Figure 3E, lane 1), while treatment with exogenous
BMP4 protein resulted in a high pSmad1 accumulation (lane 5).
The suppression of pSmad1 by Jiraiya was also observed in
these dissociated animal cap cells treated with exogenous
BMP4 protein (lanes 6 and 7). Thus, Jiraiya inhibits BMP
signaling in a cell-autonomous manner downstream of BMP
ligands and upstream of Smad1/5/8 phosphorylation.
Unlike the BMP4-induced luciferase activity, which was mark-
edly suppressed by Jiraiya (Figure 3C, lanes 4 and 5), the
reporter activity induced by constitutively active type I BMPR
(caAlk2) was not inhibited by Jiraiya (Figure 3F, lanes 4 and 5)
(Smad6 for positive control, lane 6). Consistent with this observa-
tion, the Smad1/5/8 phosphorylation induced by caAlk2 in disso-
ciated animal cap cells was not reduced by Jiraiya (Figure 3G,
lanes 4 and 5).
Collectively, these observations suggested that Jiraiya inter-
feres with BMP signaling downstream of the BMP ligands and
upstream of type I BMPR activation.
In contrast, Jiraiya did not suppress the induction of Mix.2,
a direct target gene of Activin/Nodal signaling (Chen et al.,
1996), by Activin in the animal cap (Figure S2D). Consistent
with this result, Jiraiya reduced neither Activin-induced lucif-
erase reporter activity (ARE-luc) (Figure 3H, lane 4) nor Activin-
induced Smad2/3 phosphorylation in the animal cap (Figure 3I,
lanes 5 and 6). In addition, Jiraiya did not inhibit the induction
of Xbra or the accumulation of phosphorylated Erk by bFGF
(Figures S2E and S2F). These observations showed that the
signaling inhibition by Jiraiya is not nonspecific for all inductive
signals, but instead occurs in a selective manner, even among
TGF-b family signals.
Jiraiya Attenuates the Localization of Type II BMPR
Proteins on the Cell Surface
Immunostaining of animal cap cells showed that HA-tagged
Jiraiya was more preferentially enriched in the cytoplasmic
area (in particular, perinuclear and subcortical zones) than at
the plasma membrane (Figure 4A). While no typical ER-retention
motif (Teasdale and Jackson, 1996) is found in the primary struc-
ture of Jiraiya, a coexpression study with DsRed2marker with an
ER-retention signal showed that the cytoplasmic Jiraiya staining
largely coincided with this marker (Figures 4B and 4C).
This subcellular localization of Jiraiya led us to test the possi-
bility that Jiraiya affects the trafficking of BMPR by coexpressing
Jiraiya with epitope-tagged BMPR subunit proteins in animal
cap cells. The subcellular localization of BMPRI proteins (Alk3,
Alk2, and caAlk2) (see Figures S3A–S3F) was largely unaffected
by the coexpression of Jiraiya. Interestingly, in contrast, BMPRII
largely disappeared from the plasma membrane region in the
Jiraiya-overexpressing cells (Figures 4D, left bottom; compare
with the top-left panel) (this phenomenon was seen withredissociated, and cultured in CMFM containing 1 ng/ml BMP4 protein until
stage 15.
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Figure 3. Jiraiya Inhibits BMP Signaling at the Receptor Level
(A) Schematic of the animal cap experiments. mRNAs and MOs were injected into all the blastomeres of four-cell embryos, and animal caps were prepared at
stage 9. In dissociation culture experiments, isolated animal caps were dissociated in CMFM and cultured with or without exogeneous factors.
(B) Phosphorylation of Smad1/5/8 (pSmad1) was detected by Western blot. Animal caps injected with Jiraiya (200 or 800 pg/cell) or dominant-negative Alk3
(dnAlk3, 200 pg/cell) were harvested at stage 11.
(C and D) Luciferase reporter assays performed with the BRE-luc (50 pg/cell) and phRL null (2 pg/cell, as an internal control) reporter plasmids. (C) The reporter
plasmids were coinjected with Jiraiya (400 pg/cell), dnAlk3 (200 pg/cell), and BMP4 (10 pg/cell) mRNA. (D) The reporter plasmids were injected with Jiraiya50MO
(3 ng/cell), five base-mismatched-control MO (3 ng/cell), and Jiraiya mRNA (200 pg/cell).
(E) Effects of Jiraiya on pSmad1 accumulation shown by western blotting. RNA-injected animal caps were dissociated and cultured with or without exogenous
BMP4 protein (50 ng/ml) for 2 hr.
(F and G) Effect of Jiraiya on BMP signaling induced by constitutively active type I BMPR. (F) Luciferase assay. Jiraiya (400 pg/cell), constitutively active Alk2
(caAlk2, 50 pg/cell), Chordin (50 pg/cell), and Smad6 (400 pg/cell) mRNAs were injected with the reporter plasmids. Chordin was used to minimize the endog-
enous BMP signals. Smad6 was used as a positive control.
(G) Western blotring for pSmad1. Jiraiya- (200 pg or 800 pg/cell), caAlk2-, and Smad6-injected animal cap cells were cultured in CMFM for 2 hr.
(H) Luciferase assay performedwith theARE-luc reporter plasmid (50 pg/cell). The reporter plasmids were injectedwith Jiraiya (400 pg/cell) andActivin (1 pg/cell).
(I) Western blot analysis of the Smad2/3 phosphorylation. Jiraiya (200 pg or 800 pg/cell) injected animal cap cells were cultured with or without Activin protein
(50 ng/ml) for 2 hr in CMFM.
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Figure 4. Overexpressed Jiraiya is Prefer-
entially Detected in the ER and Interferes
with the Surface Localization of BMPRII
(A–C) Subcellular localization of Jiraiya protein in
stage 9 animal cap cells. Jiraiya-HA (50 pg/cell),
the plasma membrane marker Lyn-RFP (50 pg/
cell), and the ER marker DsRed2-ER (50 pg/cell)
were injected into all the blastomeres of four-cell
embryos.
(D) Immunostaining of BMPRII protein in stage 11
animal cap explants. Xenopus BMPRII-HA
(200 pg/cell) were injected with (lower panels) or
without (upper panels) Jiraiya-myc (200 pg/cell).
(E and F) Subcellular localization of BMPRII protein
in stage 9 animal cap cells. The mRNAs (BMPRII-
3xV5, 200 pg/cell; Jiraiya-HA, 200 pg/cell;
DsRed2-ER, 100 pg/cell) were injected into all
the blastomeres of four-cell embryos.
(G and H) No obvious effects of coinjection of
Jiraiya-myc (200 pg/cell) on the surface localiza-
tion of ActRIIA-HA (50 pg/cell).
(I and J) Jiraiya-myc still caused the delocalization
of BMPRII-HA, even when endocytosis was
blocked by coinjection of dnDynamin (400 pg/
cell). The scale bar represents 20 mm.
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Jiraiya, a BMPRII-Selective Negative ModulatorBMPRII protein caused by BMPRII mRNA injection even at
a low dose) (Figures S3G–S3I), andwas substantially colocalized
with Jiraiya (Figures 4D, middle and right). Their colocalization
was further confirmed by high-resolution confocal imaging
with deconvolution (Figures 4E and 4F; Figures S3J–S3M and
Movie S1 for 3D rendering). In contrast, Jiraiya did not inhibit552 Developmental Cell 19, 547–561, October 19, 2010 ª2010 Elsevier Inc.the plasma membrane localization of the
type II Activin receptor (ActRIIA) (Figures
4G and 4H) in animal cap cells.
These findings support the idea that
Jiraiya overexpression interferes with the
intracellular transport of BMPRII to the
cell surface. The enhanced endocytosis
by Jiraiya (receptor endocytosis is re-
viewed in Wu and Hill, 2009) is unlikely,
since the overexpression of dominant-
negative dynamin (dnDynamin), which
blocks the endocytosis of surface
membrane proteins (Figures S3N and
S3O) (Jullien and Gurdon, 2005), did not
affect the disappearance of the cell
surface BMPRII by Jiraiya (Figures 4I
and 4J).
A cell surface protein labeling study
with an impermeable reagent (sulfo-
NHS-Biotin) showed that the level of
surface BMPRII protein was substantially
decreased by the coinjection of Jiraiya
in animal cap cells (Figure 5A, lanes 2
and 4, top row, and Figure 5B, closed
columns for quantification), whereas the
total BMPRII content in the lysate was
little changed (Figure 5A, second row).
In contrast to the clear suppression ofsurface BMPRII, the level of surface ActRIIA protein was little
changed by Jiraiya (Figure 5A, third row, and Figure 5B, open
columns). The specific reduction in the level of surface BMPRII,
but not of ActRIIA, by Jiraiya is consistent with its specific inhib-
itory effect on BMP signaling, and not on Activin signaling
(Figure 3).
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by the BMPRII-Specific Tail Domain
Deletion analysis (Figure 5C) showed that the extracellular
domain of BMPRII was unnecessary for its delocalization by
Jiraiya (Figures 5D and 5E). In contrast, deletion of the C-terminal
tail domain (TD) strongly reduced the sensitivity of BMPRII to
Jiraiya (BRII-dTD; Figures 5F and 5G; in figures, BMPRII is abbre-
viated to BRII). TD is a region unique to BMPRII, and no other
TGF-b family receptor has a similar structure (Frisch and Wright,
1998; Chan et al., 2007; Miyazono et al., 2010). We next added
this TD region to the C terminus of ActRIIA, which normally lacks
a TD-like domain (Figure 5C) and is insensitive to Jiraiya (Figures
4H and 5B). The surface localization of TD-fused ActRIIA
(ARIIA-TD) was clearly inhibited by Jiraiya (Figures 5H and 5I).
These findings indicate that Jiraiya specifically inhibits the
surface localization of BMPRII in a TD-dependent fashion.
A similar intracellular retention of BMPRII (and not of BRII-dTD)
was also caused by Jiraiya-dC, which lacks the intracellular
domain, and consists mainly of the three transmembrane
domains (Figures S4A–S4E). Consistent with this finding,
Jiraiya-dC was sufficient to inhibit BMP signaling in the animal
cap (Figures S4F–S4J) (BRE-luc and pSmad1 assays with
BMP4 and caAlk2), showing that the retention-promoting activity
of Jiraiya does not require its long intracellular C-terminal
domain.
We next examined whether Jiraiya and BMPRII formed
a complex in the cell, by performing a coimmunoprecipitation
assay with animal cap cell extracts. In this assay, BMPRII, but
not ActRIIA, was efficiently precipitated with Jiraiya (Figure 5J,
lanes 2 and 4; Figure S4K, for low-dose injection data), indicating
that Jiraiya preferentially associates with BMPRII. Jiraiya also
showed moderate but substantial binding to the ARIIA-TD
chimera (Figure 5J, lane 6), suggesting that the TD of BMPRII
contributes to the physical interaction between Jiraiya and
BMPRII at least to some extent.
Rather unexpectedly, we also noticed that BMPRII lacking the
TD could coprecipitate with Jiraiya (Figure 5K, lane 6), suggest-
ing that their physical interaction involves an additional domain.
Further deletion analysis of the BMPRII domains (Figure S4L) re-
vealed that the extracellular and kinase domains were unneces-
sary for its coprecipitation (Figure S4M, lanes 3 and 4; instead,
these domains could be rather inhibitory for the association).
Furthermore, a largely deleted BMPRII mutant consisting mainly
of the transmembrane domain (TM) and TD (Figure 5L) (BRII-TM/
TD) was sufficient for strong association with Jiraiya (Figure 5M,
lane 4). Swapping the TM with the transmembrane domain of
ActRIIA reduced the level of coimmunoprecipitation (Figure 5M,
lane 6; compare with lane 4), suggesting that the TM domain is
a reasonable candidate for the additional domain involved in
binding Jiraiya. This idea was further supported by another
domain-swapping analysis with the full-length receptors (Figures
5N–5P). When the TM of ActRIIA was replaced with the TM of
BMPRII (Figure 5N, bottom), the chimeric ActRIIA was substan-
tially coprecipitated with Jiraiya (Figure 5O, lane 4), unlike the
wild-type ActRIIA (lane 2). Conversely, the chimeric BMPRII
receptor in which the TM domain was replaced with ActRIIA’s
TM (Figure 5N, second row) showed relatively low binding to
Jiraiya (Figure 5P, lanes 4; compare with lane 2). Thus, it was
considered that the TM of BMPRII is involved in the physicallyDevelopmassociation to Jiraiya. On the other hand, the TM of ActRIIA,
which has presumably a relatively weak affinity, can contribute
to the association only in the presence of BMPRII’s TD domain.
Collectively, these results indicate that the unique TD of
BMPRII is crucial for its selective functional interaction with
Jiraiya, while its physical association depends on the combina-
tion of its TD and TM.
The Conserved EVNNNG Motif Plays a Key Role in the
Specific Interaction of BMPRII with Jiraiya
Although previous studies have suggested diverse roles for the
TD in modulating non-Smad signal pathways (e.g., interacting
with LIMK and c-Src) (Foletta et al., 2003; Wong et al., 2005),
its function in the BMPRII localization has not been reported.
Therefore, to elucidate the molecular control of the receptor
retention, we performed a systematic deletion analysis within
the TD region. The TD contains several motifs that are highly
conserved among the vertebrate BMPRII proteins (A–I in
Figure 6A) (Wong et al., 2006). In the systematic deletion analysis
of each motif (Figures 6B–6I), only the elimination of the H motif
(1008–1013) had a strong impact on the BMPRII delocalization
by Jiraiya (Figure 6H; controls are shown in Figures S5A–S5J).
This H motif consists of an EVNNNG sequence, which is
completely conserved among the vertebrate BMPRII proteins
(Figure 6J). The sequential replacement of each residue with
alanine showed that each of EVNNN residues was essential for
the Jiraiya-induced reduction of surface BMPRII (Figures 6K–
6Q; Figures S5K–S5Q for controls). Conversely, the addition of
the H motif (with a few flanking residues, 1004–1019) to the
TD-deleted BMPRII (Figure 6R, second row) was sufficient to
recover its susceptibility to Jiraiya (Figures 6S and 6T). Similarly,
the addition of the H motif to ActRIIA (Figure 6R, bottom row)
caused its delocalization by Jiraiya (Figures 6U and 6V). Further-
more, unlike the wild-type BMPRII, the mutant BMPRII at the H
motif (E1008A) significantly reversed the anti-BMP effect of Jir-
aiya in the animal cap assay (Figure S5R).
Next, we examined whether the in vivo function of Jiraiya
depends on endogenous BMPRII in embryonic neural
patterning. The inhibition of BMPRII by BMPRII-50MO, which
targets the 50 UTR and reduces the total amount of BMPRII
(see Figure S6A for rescue control), decreased the expression
of Pax3 and Msx1 in the neurula embryo (85% [n = 20] and
100% [n = 20], respectively; Figures 7A and 7B), showing that
the dorsal neural differentiation requires BMPRII. This depletion
of BMPRII was phenotypically epistatic to the loss of function of
Jiraiya (Jiraiya-MO), which per se expands their expression
(Figures 1G and 1I), because the injection of both MOs resulted
in the suppression of Pax3 andMsx1, likeBMPRII-50MO injection
alone (88% [n = 17] and 94% [n = 17], respectively) (Figures 7C
and 7D). This finding indicated that the major function of Jiraiya
in the transcriptional regulation of these BMP target genes is
dependent on BMPRII in vivo.
Finally, we examined whether the C-terminal region containing
the H motif plays a regulatory role in the restriction of endoge-
nous BMPRII activity in vivo. Since the knock-in technique is
currently unavailable in Xenopus, we took the following alterna-
tive approach. Motifs G–I are encoded in exon 13 (Figure 7E),
whereas motifs A–F are located in exon 12. We designed an
MO targeting the splicing donor site for exon 12 (E12SD-MO)ental Cell 19, 547–561, October 19, 2010 ª2010 Elsevier Inc. 553
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Jiraiya, a BMPRII-Selective Negative Modulator(Figures 7E and Figures S6D), which efficiently blocked the
proper splicing of intron 12, thereby producing aberrant splicing
variants that did not encode the Hmotif (Figures 7F and 7G) (note
that the total amount of BMPRII transcripts indicated by the PCR
product of exon1–exon7 was little changed) (Figure 7F, bottom,
lane 4; see Figures S6E–S6G for structural details).
As expected, Jiraiya did not affect the surface localization of
the L1/L2 (Figure 7H) or S1 (Figure 5G) (the translated product
of S1 is the same as that of BRII-dTD) variants. Importantly, these
variants were able to transduce BMP signaling in a manner
similar to wild-type BMPRII. In the dissociated animal cap assay
in which endogenous BMPRII protein was suppressed by
BMPRII-50MO (Figure 7I, lanes 2 and 3), these variants rescued
the BRE-luc activity (lanes 5 and 6) as efficiently as the wild-
type BMPRII (lane 4; lane 7 is a negative control of a mutant in
the kinase domain).
We then evaluated the function of the E12SD-MO-induced
BMPRII variants for the in vivo regulation of Pax3 and Msx1
expression. Importantly, in contrast to BMPRII50MO, which
attenuated the expression of the dorsal neural genes (Figures
7A and 7B), the injection of E12SD-MO caused a clear expansion
of Pax3 and Msx1 expression (77% [n = 13] and 100% [n = 10],
respectively) (Figures 7J and 7K). In this case, again, the expan-
sion of the dorsal marker expression by E12SD-MO was
completely reversed by the coinjection of BMPRII50MO (Msx1,
93% [n = 15] and Pax3 [79%, n = 19]) (Figure 7L and data not
shown). This result confirms that the effect of E12SD-MO, like
that of Jiraiya-MO, is dependent on BMPRII. In addition,
E12SD-MO injection increased the level of pSmad1 in the dorsal
neural tube on the injected side (Figure 7M), mimicking the effect
of Jiraiya-MO (Figure 2B). Thus, the forced selective deletion of
the C-terminal domain of endogenous BMPRII by E12SD-MO
caused a gain, rather than a loss, of BMPRII’s function.
These findings support the idea that the C-terminal region
plays an important role in the quantitative regulation of BMPRII
activity required for the developing neuroectoderm, and that
Jiraiya contributes to this essential restriction of BMPRII, at least
in part.
DISCUSSION
Jiraiya Actively Controls the BMPRII Level
on the Cell Surface
Here, we reveal that Jiraiya negatively regulates the functional
level of a BMPR component (BMPRII) on the cell surface, thereby
reducing cellular response to BMP signals. Unlike BMP-signalFigure 5. The Tail Domain of BMPRII Is Essential for the Selective Fun
(A) Western blot analysis of cell surface receptors in animal cap cells. Animal caps
(100 pg or 200 pg/cell) were dissected at stage 11. Then, the cell surface proteins
and precipitated by Neutravidin Agarose Resins.
(B) The relative efficacy of surface labeling was quantified and normalized to lysa
(C) Schematic of the BMPRII and ActRIIA constructs. SP, signal peptide; TM, tra
(D–I) Immunostaining of type II receptor proteins represented in (C). BRIIDEx-HA
(200 pg/cell; H and I) were injected into all the blastomeres of four-cell embryo
caps were fixed at stage 11.
(J–P) Coimmunoprecipitation studies to analyze the protein-protein interaction
analyzed in (M), and those in (O) and (P), are shown in (L) and (N), respectively.
BRIIDTD-HA (50 pg/cell), BRII-TD-HA (200 pg/cell), BRII-TM/TD-HA (200 pg/cel
B-HA (40 pg/cell) were injected with or without Jiraiya-myc (200 pg/cell). Animal
Developmmodulators that act on an individual Smad pathway, Jiraiya is
an anti-BMP regulator that works at the receptor levels, and
therefore, modulates BMP signals in both Smad and non-
Smad pathways. The subunit-selective regulation of BMPRII is
also intriguing with respect to the qualitative control of BMP
signaling, since previous studies have shown that ActRII can
also associate with BMPRI and contributes to BMP signal trans-
duction in some contexts (Yu et al., 2005; Miyazono et al., 2010).
In Drosophila, the membrane protein Commissureless inhibits
the surface transport of Robo from the Golgi apparatus. In this
case, the Robo transport is directed to the endosome (Dickson
and Gilestro, 2006). Regarding the fate of the BMPRII proteins
bound to Jiraiya, our preliminary analysis showed that Jiraiya
did not cause a significant increase in the polyubiquitination or
sumoylation level of BMPRII (data not shown), indicating that
Jiraiya does not simply act by increasing the degradation of
BMPRII. In accordance with this finding, the total protein level
of BMPRII in the lysate measured by western blotting did not
appear to be lowered in the Jiraiya-injected cells (Figure 5A,
lane 4, second row). Whether the BMPRII proteins that are
trapped in the cytoplasm can function as a reservoir (from
which BMPRII is released later in a different context) is an
intriguing question for elucidating the dynamic changes in
cellular responsiveness.
Oneweakness of our present study is that, because of the lack
of their antibodies, the protein analyzes (e.g., immunoprecipita-
tion and subcellular localization) of Xenopus Jiraiya and BMPRII
were based on their overexpressed (epitope-tagged) proteins
rather than on endogenous ones. Therefore, it remains to be
unambiguously determined in future investigation whether the
altered localization is the only mechanism of BMPRII attenuation
by Jiraiya or whether endogenous Jiraiya may also interfere with
BMP signaling via endogenous BMPRII expressed on the cell
surface. In fact, high-resolution imaging analysis suggested
some immunostaining signals of Jiraiya on the cell surface (and
its colocalization with remaining surface BMPRII) in animal cap
cells (data not shown; also Figure 4B). In future study, it will be
important to revisit this question once good antibodies against
endogenous proteins become available. In addition, the subcel-
lular localization and functional interactions of their mammalian
counterparts are worth analyzing in mammalian cultured cells.
Domain-Specific Mechanism of BMPRII Regulation
by Jiraiya
An obvious structural difference between BMPRII and ActRII is
that the former has a long TD at the C terminus. Importantly,ctional Interaction by Jiraiya
injected withBMPRII-V5 (200 pg/cell), ActRIIA-HA (20 pg/cell), and Jiraiya-myc
were biotinylated with a cell-impermeable labeling reagent (Sulfo-NHS-Biotin)
te (column 2 = 100).
nsmembrane domain.
(200 pg/cell; D and E), BRIIDTD-HA (50 pg/cell; F and G), and ARIIA-TD-HA
s with (E, G, and I) or without (D, F, and H) Jiraiya-myc (200 pg/cell). Animal
between Jiraiya and BMPRII. Schematic illustrations of receptor constructs
BMPRII-HA (200 pg/cell), ActRIIA-HA (20 pg/cell), ARIIA-TD-HA (200 pg/cell),
l), ARIIA-TM/TD-HA (200 pg/cell), BRII-TM/A-HA (200 pg/cell), and ARIIA-TM/
caps were cultured until stage 11 and subjected to immunoprecipitation.
ental Cell 19, 547–561, October 19, 2010 ª2010 Elsevier Inc. 555
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Figure 6. The Conserved H Motif at the C Terminus of BMPRII Is Responsible for the Selective Interaction with Jiraiya
(A) Evolutionarily conserved motifs in the tail domain of vertebrate BMPRII (red box, A–I).
(B–I) Distribution of HA-tagged BMPRII deletion constructs (DA, D554649; DB, D650744; DCD, D745838; DE, D839914; DF, D915964; DG, D9651007;
DH,D10081013;DI,D10201048) coexpressedwith Jiraiya-myc in stage 11 animal caps. RNAs (200 pg each/cell) were injected into all the blastomeres of four-
cell embryos.
(J) The EVNNNG motif is highly conserved among vertebrate species.
(K–Q) Intracellular localization of alanine substitutionmutants of the residue in the EVNNNGmotif. Mutant BMPRII mRNA (200 pg/cell) was coinjected with Jiraiya-
myc (200 pg/cell).
(R) The EVNNNG motif was fused with BRIIDTD and ActRIIA, which are insensitive to Jiraiya.
(S–V) BRIITD1004-1019-HA (50 pg /cell) and ARIIATD1004-1019-HA (20 pg/cell) were injected with (T and V) or without (S and U) Jiraiya-myc (200 pg/cell).
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Jiraiya, a BMPRII-Selective Negative Modulatorthis TD is essential for the susceptibility of BMPRII to Jiraiya, and
the addition of the TD is sufficient for ActRIIA to become sensi-
tive to Jiraiya. While our deletion and swapping analyses
indicate that both TD and TM contribute to BMPRII’s physical
association with Jiraiya, only the TD plays a major functional
role in the selective reduction of the surface receptor (Figure 5).
Given that the TM of ActRIIA can also interact with Jiraiya to
some extent in the presence of BMPRII’s TD (albeit weakly)
(Figure 5M, lane 6), one explanation may be that exchanging
the two TMs causes a quantitative change in the binding that
has only a moderate (or subthreshold) influence on the BMPRII
localization. This would be in contrast to the effect of the TD,
the presence or absence of whichmakes a qualitative difference,
contributing to the strong selectivity.
BMPRII forms a complex with Jiraiya via its TM and TD. Within
the TD, the short region near the C terminus (containing the H
motif) is essential and sufficient for the selective BMPRII
retention and can completely rescue the TD activity. This domain
contains the EVNNNG residues, which are completely con-
served among the vertebrate BMPRII proteins, while the role of
this motif has not been reported. The EVNNNG motif is particu-
larly responsible for the selective reduction of the surface
BMPRII protein, suggesting that this motif in the TD plays a crit-
ical role in creating some functional interface between BMPRII
and Jiraiya. Therefore, without the EVNNNG motif, the complex
formation with Jiraiya alone is not sufficient for the efficient inhi-
bition of BMPRII.
So far, our database search has failed to find this motif in other
receptor proteins. The Drosophila BMPRII homolog (Wit) has
a moderately conserved TD-like domain, but lacks the H motif
(the conservation between vertebrate and fly BMPRII is generally
low near the C terminus). Similarly, although a Jiraiya homolog is
found in a wide variety of vertebrates (Figure S7A), its counter-
part is not found in the fly database. Therefore, it is possible
that the active BMPRII retention by Jiraiya is specific to verte-
brates. This idea is also compatible with the finding that Jiraiya
has only one homolog set in each diploid animal genome, sug-
gesting that this gene was created after the general genomic
duplication linked to vertebrate evolution (Ohno, 1970; Kasa-
hara, 2007). So far, we have failed to detect a clear neural-
specific localization of mammalian Jiraiya (Tmem221) in the early
mouse embryo, whereas it is substantially expressed in the
developing lung and kidney of the late fetus (Figures S7B and
S7C) (its expression in these two organs is intriguing, given
that their development is known to be highly BMP-dependent)
(Warburton et al., 2000; Simic and Vukicevic, 2005).
The directed alternative-splicing manipulation (Figure 7)
clearly demonstrated the importance of the C-terminal H/I
domains in the dynamic quantitative control of BMPRII signaling
(regardless of its relevance to Jiraiya in theory). In future investi-
gation, it will also be intriguing to see whether a similar principle
is applicable to mammalian BMPRII, the activity level of which is
shown to be relevant to genetic disorders, such as idiopathic
pulmonary hypertension (Lane et al., 2000), and whether any
genetic interactions are found with mammalian Jiraiya.
In Vivo Role of Jiraiya in Early Embryonic Patterning
In ectodermal patterning, high BMP signaling plays instructive
roles in the differentiation of the epidermis, the neural crest,Developmand the dorsal-most part of the neural tube (roof plate).
Conversely, for neuroectodermal development, BMP signaling
needs to be attenuated to the proper extent in a stage-depen-
dent fashion. Early exposure of neuroectodermal progenitors
to high BMP signals directs them into the nonneural or neural
crest lineages (Liem et al., 1995; Patthey et al., 2009). At this early
stage (i.e., early gastrulation), the neural progenitors are pro-
tected from diffuse BMP signals by neural inducers, such as
Chordin and Noggin, from the organizer, which is located within
the proximity of the whole neuroectoderm. Subsequently (from
late gastrulation to neurulation), the organizer tissue converges
into a narrow axial structure (e.g., notochord), the position of
which is separated at a distance from the presumptive dorsal
neural tissue. Since the dorsal neuroectoderm is now exposed
to strong BMP signals emanating from the roof plate and the
nonneural ectoderm, local BMP signaling needs to bemodulated
to the proper (low to moderate) extent in order to avoid hyper-
dorsalization. Active restriction of the BMP signaling level is
particularly important, because BMP ligands (e.g., BMP4) are
known to augment their own transcription in a self-activating
fashion (Onichtchouk et al., 1996; Schuler-Metz et al., 2000;
Karaulanov et al., 2004).
Jiraiya appears to function as an effective high-cut filter in this
respect. At the open neural plate stages, the Jiraiya-expressing
neuroectoderm is flanked by the BMP4+ ectoderm (nonneural
ectoderm plus neural plate boundary), and, after neural tube
closure, the Jiraiya+ dorsal neural tissue is adjacent to the
BMP-expressing roof plate. The knockdown of zygotic Jiraiya
increases the level of pSmad1 in the dorsal neural tube and
expands the expression of dorsal neural markers that are posi-
tively regulated by BMP signals in vivo. These observations
demonstrate that Jiraiya limits the extent of BMP signaling during
neuroectodermal patterning, thereby preventing the hyperdors-
alization of the tissue (the role of Jiraiya for neural crest develop-
ment might be slightly more intricate, since we found that the
attenuation of Jiraiya increased the expression of the early neural
crest marker Snail, but decreased the expression of Slug and
FoxD3, whereas Jiraiya overexpression suppressed the expres-
sion of all these markers like BMPRII50MO injection) (Figures
S1Q–S1Y).
Importantly, zygotic Jiraiya expression itself is negatively
regulated by BMP signaling (Figure 1B, lanes 1 and 2), which,
in turn, is reduced by Jiraiya. This double-negative relationship
forms a feedback loop that works eventually as positive feed-
back (Figures S7D and S7E), and, in theory, can create a chain
reaction that leads to a bistable status of Jiraiya expression.
This makes particularly good sense in the developing neuro-
ectoderm, where such a bistable regulatory system could be
advantageous for the stable coexistence of Jiraiya-high/BMP-
low and Jiraiya-low/BMP-high ectodermal domains side by
side along the DV axis in the morphogenetic field. We infer
that the Jiraiya+ neuroectoderm responds to BMP signals in
a moderate but dose-dependent manner for dorsal neural
patterning, presumably via the remaining BMPRII and the unaf-
fected ActRII. In addition, it appears that, whereas high BMP
signals suppress Jiraiya expression, its expression is also
dependent on a low (but not null) level of BMP signals, since
the animal-cell injection of BMPRII50MO reduced Jiraiya expres-
sion (Figures S6B and S6C).ental Cell 19, 547–561, October 19, 2010 ª2010 Elsevier Inc. 557
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Figure 7. The Tail Domain of Endogenous BMPRII Is Essential for Restricting the BMP Activity in the Dorsal Neural Tissues
(A–D)BMPRII50MO (BRII50MO; 12 ng/cell; blocking the translation of the entire BMPRII) was injected into two animal blastomeres of eight-cell stage embryos with
Venus mRNA (200 pg/cell; tracer).
(C and D) Jiraiya-MO (6 ng/cell) was coinjected. Embryos were analyzed by in situ hybridization with the dorsal neural markers.
(E) Genomic structure of Xenopus BMPRII.E12SD-MO targets the splice-donor site ofBMPRII exon 12 and alters the splicing. Open box, coding region; gray box,
untranslated region; red box, sequence coding the EVNNNGmotif; blue dashed line, aberrant splicing caused by E12SD-MO; arrow, primer for RT-PCR analysis.
RT-PCR primers for E10–E13 are shown.
(F) RT-PCR analysis to confirm the blockage of normal splicing by E12SD-MO. Standard control MO (12 ng/cell) or E12SD-MO (12 ng/cell) was injected into four-
cell stage embryos and the embryos were then cultured until stage 15. L1, L2, and S1 indicate aberrantly spliced transcripts caused by E12SD-MO.
(G) Schematic structure of abnormal BMPRII proteins translated from aberrant transcripts. SP, signal peptide; TM, transmembrane domain; red box, EVNNNG
motif; green box, polypeptide translated from the intron 12 sequence.
(H) Localization of the C-terminal deletion BMPRII mutant BRII(1–965), corresponding to L1/L2, in Jiraiya-overexpressing animal cap cells. BRII(1-965)-HA
(200 pg/cell) was injected into four-cell stage embryos with Jiraiya-myc (200 pg/cell).
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Jiraiya, a BMPRII-Selective Negative ModulatorIn this study, we focused on Jiraiya’s role in neural patterning
and its molecular mechanism via BMPRII inhibition. It would be
intriguing to know whether maternal Jiraiya also plays a role in
the modulation of early neural development. Unlike zygotic
Jiraiya, however, maternal Jiraiya is evenly distributed on the
animal side, with no apparent deviation along the DV axis
(Figure S1A), and disappears before the early gastrula stage,
when neural induction occurs in the dorsal ectoderm (Sasai
and De Robertis, 1997). The exact in vivo role of maternal Jiraiya
is an intriguing topic, whose elucidation must await future inves-
tigation.
EXPERIMENTAL PROCEDURES
Isolation of Jiraiya, Plasmid Construction, and Microinjection
The differential screening for Chordin-induced genes has been described
previously (Sasai et al., 2001). Jiraiya was chosen for analysis in this study
because of its neural-specific expression in the neurula embryo. The coding
sequence of Jiraiya cDNA (AB546271) was subcloned into pCS2. For microin-
jection studies, synthetic mRNA (prepared with mMESSAGE mMACHINE;
Ambion) and MOs were injected into the blastomeres of four- or eight-cell
stage embryos (as indicated in the text and figure legends). The sequence
comparison among vertebrate Jiraiya-related proteins is shown in Figure S7A.
Embryonic Manipulation, In Situ Hybridization,
and Animal Caps Assay
The developmental stage of the Xenopus embryos was determined according
to the normal table of Nieuwkoop and Faber (1967). For the in situ hybridization
analyses, synthetic mRNA- and MO-injected embryos were fixed in MEMFA
(Sive et al., 2000) at the indicated stages. Whole-mount in situ hybridization
analyses were performed as previously described (Sasai et al., 2001). The
signals were visualized with a DIG-labeled probe with BM purple (Roche).
For the animal cap assays, the animal caps were dissected from injected
embryos at stage 9 and cultured in 13 Low Calcium and Magnesium Ringer’s
solution (LCMR) with 0.2% BSA until the indicated stage. For dissociated
animal caps assays, animal cap explants were prepared from injected
embryos at stage 9, subsequently dissociated in the calcium- and magne-
sium-free medium (CMFM) (Sive et al., 2000) supplemented with 0.2% BSA,
and cultured on four-well plates (Nunc) until the indicated stage. For reaggre-
gation culture, dissociated animal cap cells were quickly reaggregated in
LCMR with 96 well low cell-adhesion plates (Lipidure-coat U96W; Nunc) and
cultured until the indicated stage.
Antibodies and Recombinant Proteins
The anti-HA (3F10) and anti-myc (9E10) antibodies were purchased from
Roche. The anti-V5 was from Invitrogen. The anti-phospho-Smad1/5/8, anti-
phospho-Erk, anti-Erk, anti-Smad2/3, anti-myc (71D10), and anti-FLAG anti-
bodies were from Cell Signaling. The anti-HA antibody (H6908) was from
Sigma, The anti-Smad1/5/8 antibody was from Santa Cruz Biotechnology.
The anti-phospho-Smad2/3 antibody was from Chemicon. The anti-GFP
(GF090R) antibody was from Nacalai Tesque. The anti-DsRed/RFP antibody
was from Clontech. Recombinant human BMP4, recombinant human Activin
A, recombinant human FGF basic, and recombinant mouse Chordin proteins
were purchased from R&D Systems. The concentration of the commercial
recombinant proteins was calculated by referring to the manufacturer’s
product data sheet.(I) Luciferase assay to confirm the BMP signal transduction activity of abnormal B
BMPRII series (WT, 200 pg/cell; 1–965, 200 pg/cell; 1–553, 50 pg/cell; K254R, 20
plasmid (25 pg/cell). Animal cap cells were dissociated and cultured with or with
(J–L) E12SD-MO (6 ng/cell) was injected unilaterally into two animal blastomeres o
(12 ng/cell) was coinjected.
(M) Immunostaining for pSmad1 in the dorsal neural tube of the tailbud embryo i
blastomeres of eight-cell embryos with Lyn-Venus (5 pg/cell) as a lineage tracer.
DevelopmRNA Isolation and RT-PCR
Total RNA was extracted from embryos or animal cap cells with the RNeasy
Mini Kit (QIAGEN), and cDNA was synthesized with random hexamer primers
with SuperScript III (Invitrogen). Quantitative RT-PCR was performed on the
7500 Fast Real-Time PCR System (Applied Biosystems) with the Power
SYBR Green PCR Master Mix (Applied Biosystems). The gene expression
was normalized to that of ODC (Ornithine decarboxylase). For confirming the
effect of splice-interfering MOs, conventional RT-PCR analysis was per-
formed. The primer sequences are shown in Table S2.
Luciferase Reporter Assay
For luciferase assays, the reporter vector pBRE-luc, (Korchynskyi and ten
Dijke, 2002) or pARE-luc (Chen et al., 1996) was injected into all blastomeres
of four-cell embryos together with a loading control vector (phRL null;
Promaga), mRNAs, and MOs. Animal caps were excised at stage 9, cultured
until the indicated stage, and subjected to luciferase assays with the Dual-
Luciferase Reporter Assay System (Promega).
Western Blot
Western blot analyses were performed as described previously (Sato et al.,
2005). Embryos or animal caps were lysed in TNE lysis buffer (50 mM Tris-
HCl [pH 7.4], 150 mM NaCl, 1 mM EDTA, and 1% Triton X-100) containing
protease inhibitor cocktail (Nacalai). For phosphorylated protein detection,
animal cap cells were lysed in dephosphorylation blocking lysis buffer
(10 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1.5 mM MgCl2, 100 mM NaF,
1 mM EDTA, and 1% NP-40) containing protease inhibitor and phosphatase
inhibitor (Sigma). The lysate was cleared by centrifugation at 20,000 3 g for
15 min. The supernatant was subjected to SDS-PAGE and then blotted onto
a PVDF membrane (Millipore, MA). Signals were detected and quantified by
an LAS-3000UVmini (Fujifilm) with ECL reagents (GE Healthcare).
Immunoprecipitation Assay
Prepared animal caps were lysed in the TNE lysis buffer. After centrifugation,
the supernatant was immunoprecipitated using an anti-myc tag antibody
(9E10; Roche) with protein G Sepharose (GE Healthcare). The precipitates
were washed in TNE lysis buffer three times and subjected to Western blot
analysis to detect precipitated proteins.
Surface Labeling Assay
Biotin labeling of the cell surface proteins was carried out in accordance with
the manufacturer’s protocol with some modifications for Xenopus embryonic
cells. In brief, mRNA-injected animal caps were dissected at stage 11 and
directly labeled with 1 mg/ml Sulfo-NHS-Biotin (Pierce) in ice-cold Tris-free
CMFM (5 mM HEPES [pH 7.8], 88 mM NaCl, 1 mM KCl, and 2.4 mM NaHCO3)
for 1 hr. After the labeling reaction, the cells were washed three times in Tris-
free CMFM containing 100 mM glycine and lysed in TNE lysis buffer with
protease inhibitor. The cell lysate, containing the biotinylated proteins, was
centrifuged and the supernatant was subjected to a pulldown assay with
NeutrAvidin agarose resin (Thermo). The biotinylated proteins were precipi-
tated, and analyzed by western blotting.
Immunostaining
Immunostaining of Xenopus tissues was performed using a method described
previously (Schohl and Fagotto, 2003), with somemodifications. Embryos and
animal cap explants were fixed in MEMFA for 1 hr at room temperature and
then in Dent’s fixative (80% methanol and 20% DMSO) overnight at 20C.
The samples were embedded in 15% cold-water fish gelatin (Sigma) and
15% sucrose containing PBS overnight at room temperature, then in 25%MPRII. Standard control MO (25 ng/cell), BRII50MO (25 ng/cell), and mRNA of
0 pg/cell) were injected into four-cell stage embryos with the BRE-luc reporter
out 50 ng/ml BMP4 protein in CMFM.
f eight-cell stage embryos with VenusmRNA (200 pg/cell; tracer). (L)BRII50MO
njected with E12SD-MO. E12SD-MO (12 ng/cell) was injected into two animal
ental Cell 19, 547–561, October 19, 2010 ª2010 Elsevier Inc. 559
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Jiraiya, a BMPRII-Selective Negative Modulatorcold-water fish gelatin and 15% sucrose containing PBS again overnight.
Next, the samples were embedded in O.C.T. Compound (Tissue-Tek) and cry-
osectioned at 17C. The sections were quickly transferred to MAS-coated
slides and dried at room temperature. Prior to the blocking step, the sections
were treated in acetone for 1 min on ice. Immunohistochemistry was per-
formed by a conventional method. High-resolution confocal imaging was
done with the LSM710 system (Zeiss) with an oil-immersion 3100 lens
(N.A. = 1.45) and analyzed with the Imaris and AutoDeblure softwares.ACCESSION NUMBERS
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